

AAD 2025

DO NOT MISS HIGHLIGHTS IN PSORIATIC DISEASE

MARCH 2025



NEWSLETTER

TABLE OF CONTENTS

Basic Science Highlights • P. 2

Clinical Highlights • P. 3

Treatment Highlights • P. 4

Psoriasis Sessions • P. 5-6

GRAPPA Adjacent to AAD • P. 7

AAD Virtual Congress Highlights • P. 8

Y-GRAPPA members prepared this Newsletter. It highlights some of the very interesting abstracts on psoriatic disease that will be presented at the 2025 AAD Congress in Orlando.



Leandro Linhares Leite
COORDINATOR



Hanna Johnsson
COORDINATOR



Daniela Tovar
Formatting/Layout



Luciana Vilela
CONTRIBUTOR



Daniel Barquero Orias
CONTRIBUTOR



Hannah den Braanker
CONTRIBUTOR



Eva Klara Merzel Šabović
CONTRIBUTOR



Anju George
CONTRIBUTOR

BASIC SCIENCE HIGHLIGHTS

ABSTRACT

Effectiveness of SFA002 to inhibit TH1/TH17 inflammation in an experimental skin model.

Stefan Weiss MD FAAD and Alla Arzumanyan PhD

ePoster only

Why important?



SFA002 is an oral immunomodulator that targets multiple pro-inflammatory cytokines, including TNF, IL-23, IL-10, IL-12, IL-17, and IFN- γ . This sets it apart from current treatments, which typically focus on a single cytokine or pathway. It will be interesting to see the in vitro and in vivo results of this multi-cytokine approach on specific T cell populations.

IL-17A/F dual-producing T cells, unstable Tregs, and quiescent TRMs in clinically healed lesions are potential cellular candidates for recurrence of psoriasis

Peng Lu, et al

Friday 7th, 9:55 AM

Exhibit Hall B4, Poster Center 2

Given the tendency of psoriatic lesions to recur after treatment, identifying the cell populations responsible for the skin's memory could provide valuable insights into designing new therapies for longer-lasting skin remission.

Comparative RNA Sequencing Analysis of IL-17 and IL-23 Inhibitors in Psoriasis: Suppression of IL-8 Pathway and Immune Modulation

I-Chang Lai MD and Po-Yuan Wu MD

Sunday 9th, 2:55 PM

Exhibit Hall B4, Poster Center 1

Studies exploring the underlying mechanisms of existing biological treatments are scarce. This study uses RNA sequencing to reveal IL-8 as a target pathway of IL-17 and IL-23 inhibitors. (Honorable Mention in Poster Award Winners)

Expression Profiles of Galectins in Psoriasis: Insights from Analysis of Public Single-Cell RNA Sequencing Data

Kayla Danesh BS, et al.

ePoster only

Single-cell sequencing data in psoriasis is rapidly growing, offering an exciting opportunity to accelerate our understanding of the pathological molecules involved. Galectins have a wide range of biological functions, and this study may provide valuable insights into their role in psoriasis pathogenesis.

CLINICAL HIGHLIGHTS

ABSTRACT

Why important?



The impact of psoriasis on sleep quality: examining the relationship between psoriasis, sleep, and mental health

Andrea Leung MPH, et al.

Saturday, 8, 10:55 AM

Exhibit Hall B4, Poster Center 2

This study explores the connection between psoriasis, sleep disturbances, and mental health, highlighting the need for integrated management strategies to improve patient well-being.

The VISIBLE study: Burden of comorbidities in participants with moderate-to-severe psoriasis across all skin tones

Linda Stein Gold, et al.

Sunday, 9, 2:30 PM Exhibit Hall B4, Poster Center 2

This study highlights the burden of comorbidities in psoriasis across diverse skin tones, addressing a gap in equitable healthcare and improving recognition of associated risks.

Characterization of patient preferences and barriers to education on cardiometabolic risk in psoriasis: a quality improvement survey study

Caitlin Kearney BS, et al.

Saturday 8th, 3:30 PM

Exhibit Hall B4, Poster Center 1

Understanding patient preferences and barriers to cardiometabolic risk education can enhance preventive care strategies and improve long-term outcomes in psoriasis management.

Excellent Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution

Jose W. Ricardo, et al.

Friday, 7th, 3:00 PM

Exhibit Hall B4, Poster Center 2

This study demonstrates a high level of agreement between a convolutional neural network (CNN) and dermatologists in assessing nail psoriasis severity. Nail psoriasis can be challenging to evaluate, and CNN-driven scoring may offer a more objective and reproducible approach for clinical practice and research. AI-assisted tools can potentially enhance psoriasis management and contribute vastly to streamlined treatment approaches.

TREATMENT HIGHLIGHTS

ABSTRACT

Real-World Switch Rates of Biologic Therapies Over 3 Years in Patients With Psoriasis in the United States

April W Armstrong MD, et al.

ePoster only

Failure of IL-17 and IL-23 Inhibitors: Real-World Experience of Biologic Switching in Psoriasis

Teerapat Paringkarn, et al.

ePoster only

Adverse Events Associated with Bimekizumab for Moderate-to-Severe Plaque Psoriasis: A Multicenter, Post-Hoc Analysis of 46 Patients

Nikki Zangenah BA, et al.

Saturday, 8 11:05 AM

Exhibit Hall B4, Poster Center 2

The Relationship between Psoriasis, Treatment Type, and Subsequent Non-Alcoholic Steatohepatitis: A Global

TriNetX Database Study

Hannah Verma BA, et al.

Friday, 7th, 1:30 PM

Exhibit Hall B4, Poster Center 2

Impact of GLP-1 Receptor Agonists on Psoriasis: A Systematic Review and Single-Arm Meta-Analysis

Jiandra da Luz, et al.

Sunday 9th, 1:40 PM

Exhibit Hall B4, Poster Center 1

Why important?



It is important to know the switching rates of biologic therapies in psoriasis and the characteristics of patients in whom therapy was switched. This study could help to identify subgroups of patients who are more susceptible to treatment failure.

As IL-17 and IL-23 inhibitors are increasingly used in scenarios where other systemic drugs fail in psoriasis, it would be interesting to know what their switching rate is and what to do when they fail.

As bimekizumab has only been on the market for a short time, this multicenter post-hoc analysis provides an insight into adverse events.

In view of the complex interaction between psoriasis and non-alcoholic steatohepatitis, it is very important to know how the different types of treatment affect non-alcoholic steatohepatitis and, more importantly, which type of treatment could potentially alleviate both – psoriasis and non-alcoholic steatohepatitis.

GLP-1 receptor agonists (GLP-1 RAs), licensed for diabetes and weight management, have recently been explored for their potential impact on psoriasis. This study evaluates available evidence if GLP-1 RAs may be repurposed as adjunctive or alternative treatments for psoriasis. This study highlights the role of metabolic pathways as part of a holistic approach to psoriasis improvement.

PSORIASIS AT AAD 2025

Sessions You Can't Miss

Friday, March 07

9:00 am - InsS008 - **JAK Inhibitors: A New Frontier in Dermatology**

1:00 pm – S018 - **Nail Symposium**

2:15 pm – IND06 – **Obesity-related Inflammation & Psoriasis: A Conversation on the Interplay and What You Need to Know**

Saturday, March 08

9:00 am – S023 – **Psoriasis: Modern Therapeutic Approaches**

9:00 am – S024 – **Inflammatory Skin Diseases: The Translational Revolution**

3:30 pm – F055 – **Our “Joint” Goal: Pearls for the Concomitant Management of Psoriasis and Psoriatic Arthritis**

7:00 pm – INC08 – **The Patient’s Voice: Guiding the Path to Address Unmet Needs in Psoriasis**

Sunday, March 09

1:00 pm – S047 – **Therapeutic Hotline**



PSORIASIS AT AAD 2025

Sessions You Can't Miss

Monday, March 10

9:00 am – F080 – **The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients**

1:00 pm – S065 – **Great Care for Common Conditions: Combining Evidence and Cost Effectiveness**

4:30 pm – U102 – **Navigating Uncharted Waters: The Management of Autoimmune & Inflammatory Skin Disorders in Pregnant and Breastfeeding Patients**

Tuesday, March 11

8:00 am – S069 – **What's New in Dermatology**



2025 ADJACENT TO AAD



MARCH 9
6:00 - 8:00 PM

REGISTER NOW



Hyatt Regency Orlando
9801 International Drive, Orlando, FL 32819
Bayhill 25-26

FEATURING:



JOSEPH MEROLA
UT Southwestern
(USA)



ALICE GOTTLIEB
The Icahn School of
Medicine (USA)



ANDREW BLAUVELT
Blauvelt Consulting
(USA)



APRIL ARMSTRONG
University of California,
Los Angeles (USA)



ALYSSA ROBERTS
University of California,
Los Angeles (USA)



LOURDES PEREZ-CHADA
Harvard Medical School
(USA)



BETUL MACIT
Brown Dermatology
(USA)



CHERYL ROSEN
University of Toronto
(Canada)



KENNETH GORDON
Medical College of
Wisconsin (USA)



grappanetwork.org



GRAPPA

Virtual Congress Highlights AAD 2025

OF PSORIATIC DISEASE

ONLINE EVENT



DATE
APRIL 9



TIME
10:00–11:30 AM EDT
4:00–5:30 PM CEST

[**REGISTER NOW!**](#)



SCAN ME



GRAPPA
GROUP FOR RESEARCH
AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS

Y-GRAPPIAns
YOUNG GROUP FOR RESEARCH
AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS